1968 results have been found
July 31, 2019
Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan
July 4, 2019
Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.
This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.
Are you a healthcare professional?